FIELD: medicine.
SUBSTANCE: group of inventions relates to immunology and oncology. What is developed is an immunobiological agent based on mRNA, in which the mRNA contains a sequence selected from: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 8, at 5'-end; an open reading frame encoding from 1 to 80 tumour gene signatures; sequence SEQ ID NO: 6 or SEQ ID NO: 7 at 3'-end. Also disclosed is a method for preparing the agent and use thereof.
EFFECT: presented group of inventions extends the range of agents and methods for inducing immune response in patients with oncological diseases and can be used in therapy of patients with oncological diseases of various aetiologies.
5 cl, 4 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR FORMING IMMUNE SURVEILLANCE SYSTEM FOR TUMOUR CELLS IN MAMMAL BODY | 2024 |
|
RU2828654C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCING IMMUNE RESPONSE AGAINST INFLUENZA VIRUS AND USE THEREOF | 2024 |
|
RU2838904C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCING A COMPLEX IMMUNE RESPONSE AGAINST SARS-COV-2 VIRUS AND INFLUENZA VIRUS AND USE THEREOF | 2024 |
|
RU2836687C1 |
| mRNA-BASED VECTOR FOR INCREASED TARGET PROTEIN PRODUCTION IN MAMMALIAN CELLS (VARIANTS) | 2022 |
|
RU2792231C1 |
| CATIONIC LIPID FOR DELIVERY OF NUCLEIC ACIDS INTO MAMMALIAN CELLS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2024 |
|
RU2836309C1 |
| IMMUNOBIOLOGICAL AGENT AND METHOD FOR USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST EBOLA VIRUS | 2015 |
|
RU2578159C1 |
| mRNA-BASED IMMUNOBIOLOGICAL AGENT FOR PREVENTION OF DISEASES CAUSED BY TICK-BORNE ENCEPHALITIS VIRUS | 2024 |
|
RU2823754C1 |
| PLASMID DNA CARTRIDGE pVAX-C3-polyA, PLASMID DNA MATRIX pVAX-C3-RBD-polyA FOR mRNA SYNTHESIS AND POLYNUCLEOTIDE VACCINE AGAINST SARS-CoV-2, WHICH IS MOLECULES mRNA-C3-RBD-polyA WHICH INDUCE SARS-CoV-2-SPECIFIC ANTIBODIES | 2024 |
|
RU2839841C1 |
| ARTIFICIAL NUCLEIC ACID MOLECULES | 2013 |
|
RU2651498C2 |
| PLASMID pVAX-RBD DNA MATRIX OF mRNA-RBD MOLECULES, OBTAINED USING THE pVAX - RBD DNA MATRIX, PROVIDING THE SYNTHESIS AND SECRETION OF THE RBD PROTEIN SARS-CoV 2 IN MAMMALIAN CELLS AND A COMPLEX IN THE FORM OF NANOPARTICLES CONTAINING mRNA-RBD MOLECULES THAT INDUCE SARS-CoV-SPECIFIC ANTIBODIES WITH VIRAL NEUTRALIZING ACTIVITY | 2021 |
|
RU2754230C1 |
